ICAM1-Coated Nanoparticles for Targeted PAD Angiogenesis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for peripheral artery disease (PAD), such as angioplasty and drug-eluting stents, are invasive and pose risks like restenosis and thrombosis, while non-surgical methods like growth factor delivery have limited efficacy and stability.

Innovation Solution

Development of engineered cellular membrane-coated nanoparticles that mimic the extracellular matrix, expressing ICAM1 binding ligands to deliver pro-angiogenic therapeutic factors, enhancing blood flow and promoting angiogenesis in ischemic tissues.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If surgical interventions (angioplasty, stents, grafts) are used to treat PAD, then immediate restoration of blood perfusion is achieved, but invasive risks and complications increase

Engineering Contradiction:

Improverestoration of blood perfusionVSAvoidinvasive risks including restenosis, thrombosis, and graft unavailability

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses ICAM1 binding ligands as intermediaries to mediate the interaction between nanoparticles and ischemic tissue. These ligands specifically bind to ICAM1 receptors on endothelial cells at the site of arterial blockage, enabling targeted delivery of therapeutic factors without invasive surgical intervention. This mediator approach allows non-invasive treatment to achieve effects comparable to surgical interventions.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the physical and chemical parameters of therapeutic delivery by using nanoparticles with controlled size, surface charge, and degradation rate. The nanoparticles are engineered to have specific hydrodynamic diameters and zeta potentials that optimize their circulation time, tissue penetration, and cellular uptake. This parameter optimization enables non-invasive delivery to achieve immediate and sustained therapeutic effects.

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If non-surgical growth factor delivery is used to treat PAD, then invasive risks are reduced, but therapeutic efficacy and stability are limited

Engineering Contradiction:

Improveinvasive risksVSAvoidtherapeutic efficacy and stability

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent creates composite nanoparticle structures combining multiple materials with complementary properties: biodegradable polymer cores for controlled drug release, lipid membranes for stability and cellular recognition, and protein-based ICAM1 binding ligands for targeted attachment. This composite structure integrates the advantages of different material systems to achieve both low invasiveness and high therapeutic efficacy.

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent ensures continuous therapeutic action through sustained release of pro-angiogenic factors from degrading nanoparticles. The nanoparticles are designed to maintain therapeutic concentrations of growth factors over extended periods, providing continuous stimulation of angiogenesis rather than single-dose transient effects. This continuous action overcomes the stability limitations of conventional growth factor delivery.

Inventive Principle:

Principle #20Continuity of useful action

3Area of stationary object

If systemic therapeutic delivery is used, then broad coverage is achieved, but off-target effects and systemic side effects increase

Engineering Contradiction:

Improvecoverage areaVSAvoidsystemic side effects

Core Design Contradiction:

Area of stationary objectVSObject-generated harmful factors

Solution Approach 1:

The patent imparts local quality to the therapeutic action by equipping nanoparticles with ICAM1 binding ligands that specifically recognize and bind to receptors at the ischemic site. This creates a gradient of therapeutic concentration with high localization at the target tissue and minimal presence in healthy areas. The ligand-receptor interaction ensures that therapeutic factors are delivered precisely where needed, achieving local high coverage without broad systemic distribution.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The nanoparticles improve tissue perfusion and alleviate symptoms in PAD patients by targeting and stimulating new blood vessel formation with enhanced efficacy and reduced systemic side effects.

Implementation Method 1

the cellular membrane coating comprises an Intercellular Adhesion Molecule-1 alpha receptor (ICAM1 or ICAM-1) binding ligand

Methodology Applied

Scientific EffectReceptor-ligand binding: Adsorption

Implementation Method 2

deliver pro-angiogenic therapeutic factors to stimulate the formation of new blood vessels. By promoting angiogenesis, these nanoparticles enhance blood flow to ischemic tissues

Methodology Applied

Scientific EffectAngiogenesis stimulation:

Data Source

PatentUS20260034072A1Coated nanoparticles for the treatment of peripheral artery disease

Publication Date: 2026.02.05 BOARD OF RGT THE UNIV OF TEXAS SYST

AI summary

Described herein are compositions and methods for treating peripheral artery diseases, including a composition comprising a nanoparticle defining an interior volume and an exterior surface; a payload disposed within the interior volume of the nanoparticle; and a cellular membrane coating disposed on or encapsulating the exterior surface of the nanoparticle; wherein the cellular membrane coating comprises an ICAM1 binding ligand.